Taking stock of the drug industry, from the lab to the medicine chest STAT+: From buzzy biomarkers to learning from failure: 3 takeaways from the Alzheimer's Association International Conference By Jonathan Wosen Jonathan Wosen/STAT Potential biomarkers, explanations for a failed clinical trial, and the search for new treatments were hot topics at this year's meeting. Read More STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Sponsor content by STAT Events Biomarkers: The Foundation of Personalized Oncology Register for a virtual event on August 17 to hear researchers, academics, and business leaders discuss what recent innovations in biomarkers mean for the future of cancer treatments. Opinion: The next generation of illicit drugs? Think 'synthetic' By Jim Crotty Brendan Smialowski/AFP/Getty Images It is tough to predict which illicit substances will become the "next fentanyl." But they will almost certainly include synthetic drugs. Read More Friday, August 5, 2022 1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser
No comments